Skip to main content
. 2016 Jun 8;6:27530. doi: 10.1038/srep27530

Figure 1. PEG-b-PCL micelle-encapsulated citral inhibits in vivo tumor growth.

Figure 1

When the 4T1 tumor reached 50 mm3, the mice (5 per group) received three retro-orbital injections on days 1, 2 and 3 (indicated by arrows) of: NP vehicle, 2.5% DMSO, citral/DMSO or citral/NP (PEG-PCL micelle-encapsulated citral). Two concentrations of citral, 40 or 80 mg/kg, were tested. A, The control NP and DMSO treatments did not inhibit tumor growth. Compared to controls, citral/DMSO 40 and citral/DMSO 80 were similarly effective in inhibiting growth of the aggressive 4T1 tumors (p < 0.01). However, there was significantly improved tumor regression with citral/NP at both 40 (p < 0.001) and 80 mg/kg (p < 0.001) by day 10. B, the formulations did not generate acute toxicity in animals based on consistent animal weights throughout the treatment period.